Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bladder Cancer
Notice of U.S. patent allowance for superficial bladder cancer drug received
February 20th, 2005
Spectrum Pharmaceuticals, Inc. (SPPI) announced that it has received from the U.S. Patent and Trademark Office (PTO) a Notice of Allowance for its patent application for EOquin entitled "Medical Compositions for Intravesical Treatment of Bladder Cancer." This patent, when issued, protects EOquin for use in the treatment of superficial bladder cancer and will not expire until November 2022. Spectrum Pharmaceuticals announced the completion of enrollment in EOquin multi-center phase 2 trial for refractory superficial bladder cancer on January 6, 2005. The company plans to present phase 2 data on EOquin at the European Association of Urologists...
Source: Medical Letter on the CDC & FDA (2005-02-20)
|
